Insider Transactions Reported by 19 Insiders of Phathom Pharmaceuticals, Inc.

Symbol: PHAT on Nasdaq
Location: Florham Park, NJ

Quick Takeaways

PHAT - Phathom Pharmaceuticals, Inc. has 19 insiders with reported activity on this page.
Net insider value flow over the last year: -$12,195.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $14,609; sell value: $26,804.
Net share flow: +1,103.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Source Evidence

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to selling over the last 12 months. Net value: -$12,195.

Buys

$14,609

Shares: 3,780

Insiders: 1

Sells

$26,804

Shares: 2,677

Insiders: 1

Net

-$12,195

Shares: +1,103

Insiders: 0

Window (months)	Buy shares	Sell shares	Buy $	Sell $	Net $
0-3	0	0	$0	$0	$0
3-6	0	0	$0	$0	$0
6-9	0	985	$0	$12,653	-$12,653
9-12	3,780	1,692	$14,609	$14,152	+$458

Phathom Pharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Medicxi Ventures Management (Jersey) Ltd	10%+ Owner	$60,463,034			Mixed	24 Jan 2024
TAKEDA PHARMACEUTICAL CO LTD	10%+ Owner	$30,420,222			Filing P/S	24 Jan 2024
James N. Topper	Director, 10%+ Owner	$19,639,309	+$14,609	+0.07%	Mixed	03 Jun 2025
David A. Socks	Director	$11,216,740			Mixed	23 May 2024
Azmi Nabulsi	Chief Operating Officer	$10,029,637			Mixed	27 Feb 2025
Steven L. Basta	President and CEO, Director	$4,785,898			Mixed	10 Feb 2026
Sanjeev Narula	Chief Financial & Bus. Officer	$3,439,266			Mixed	02 Jan 2026
Terrie Curran	President and Chief Executive, Director	$2,399,933			Mixed	27 Feb 2025
Asit Parikh	Director	$1,602,130			Mixed	10 Mar 2026
Molly Henderson	CFO and CBO	$1,558,384			Mixed	07 Apr 2025
Anne Marie Cook	Chief Legal Off. & Corp. Sec.	$1,136,621			Mixed	10 Feb 2026
Robert Charles Breedlove	Principal Accounting Officer	$857,130	-$26,804	-3%	Mixed	27 Feb 2026
Frank Karbe	Director	$223,425			Mixed	03 Jun 2025
Michael F. Cola	Director	$131,731			Mixed	03 Jun 2025
Mark Stenhouse	Director	$99,300			Mixed	03 Jun 2025
Heidi Fields	Director	$99,300			Mixed	03 Jun 2025
Theodore R. Schroeder	Director	$95,577			Mixed	16 Apr 2025
Anthony J. Guzzo	VP, Chief Accounting Officer	$71,787			Mixed	19 Jan 2022
Tadataka Yamada	Director				Mixed	21 May 2021

Top shareholders of Phathom Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Frazier Life Sciences Management, L.P.	13F	Company	16%	12,466,489	$138,502,693	—	31 Mar 2026	13F
Medicxi Ventures Management (Jersey) Ltd	13F 3/4/5	Company · 10%+ Owner	9.5%	7,464,572	$82,931,395	—	31 Mar 2026	13F 3/4/5
Frazier Life Sciences Public Fund, L.P.	13D/G	James N. Topper	8.6%	5,985,327	$70,447,299	$0	01 Nov 2025	13D/G
MILLENNIUM MANAGEMENT LLC	13D/G 13F	Company	5.3%	4,178,411	$51,101,967	+$25,636,905	06 Mar 2026	13D/G 13F
Invesco Ltd.	13F	Company	5.5%	4,322,060	$48,018,086	—	31 Mar 2026	13F
BlackRock, Inc.	13F 13D/G	Company	4.6% from 13D/G	4,061,996	$45,128,776	—	31 Mar 2026	13F 13D/G
Carlyle Group Inc.	13F 13D/G	Company	4.9% from 13D/G	3,496,808	$38,849,537	—	31 Mar 2026	13F 13D/G
TAKEDA PHARMACEUTICAL CO LTD	3/4/5	10%+ Owner	— class O/S missing	3,755,583	$30,420,222	—	24 Jan 2024	3/4/5
VANGUARD CAPITAL MANAGEMENT LLC	13F	Company	3.3%	2,583,636	$28,704,196	—	31 Mar 2026	13F
NEA Management Company, LLC	13F	Company	2.5%	1,960,169	$21,777,478	—	31 Mar 2026	13F
683 Capital Management, LLC	13F	Company	2.3%	1,850,000	$20,553,500	—	31 Mar 2026	13F
James N. Topper	3/4/5	Director, 10%+ Owner	— mixed-class rows	5,950,827 mixed-class rows	$19,639,309	+$14,609	03 Jun 2025	3/4/5
Ensign Peak Advisors, Inc	13F	Company	2.1%	1,627,806	$18,084,925	—	31 Mar 2026	13F
Catalys Pacific, LLC	13F	Company	1.9%	1,493,854	$16,596,718	—	31 Mar 2026	13F
GW&K Investment Management, LLC	13F	Company	1.8%	1,421,109	$15,789,000	—	31 Mar 2026	13F
STATE STREET CORP	13F	Company	1.8%	1,386,890	$15,408,348	—	31 Mar 2026	13F
WASATCH ADVISORS LP	13F	Company	1.7%	1,340,916	$14,897,577	—	31 Mar 2026	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.7%	1,328,045	$14,756,816	—	31 Mar 2026	13F
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.	13F	Company	1.5%	1,205,369	$13,392,000	—	31 Mar 2026	13F
David A. Socks	3/4/5	Director	— mixed-class rows	1,248,756 mixed-class rows	$11,216,740	—	23 May 2024	3/4/5
SummitTX Capital, L.P.	13F	Company	1.3%	995,885	$11,064,282	—	31 Mar 2026	13F
FRANKLIN RESOURCES INC	13F	Company	1.3%	994,504	$11,048,939	—	31 Mar 2026	13F
PERCEPTIVE ADVISORS LLC	13F	Company	1.2%	925,000	$10,276,750	—	31 Mar 2026	13F
Azmi Nabulsi	3/4/5	Chief Operating Officer	— mixed-class rows	1,406,436 mixed-class rows	$10,029,637	—	27 Feb 2025	3/4/5
MARSHALL WACE, LLP	13F	Company	1.1%	860,692	$9,562,288	—	31 Mar 2026	13F
Propel Bio Management, LLC	13F	Company	1.1%	841,272	$9,354,403	—	31 Mar 2026	13F
VANGUARD PORTFOLIO MANAGEMENT LLC	13F	Company	0.84%	666,029	$7,399,582	—	31 Mar 2026	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.79%	626,196	$6,957,038	—	31 Mar 2026	13F
EcoR1 Capital, LLC	13F	Company	0.79%	625,000	$6,943,750	—	31 Mar 2026	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.61%	482,136	$5,356,531	—	31 Mar 2026	13F
Steven L. Basta	3/4/5	President and CEO, Director	— mixed-class rows	774,471 mixed-class rows	$4,785,898	—	10 Feb 2026	3/4/5
StepStone Group LP	13F	Company	0.54%	422,085	$4,689,364	—	31 Mar 2026	13F
NORTHERN TRUST CORP	13F	Company	0.53%	414,956	$4,610,160	—	31 Mar 2026	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.52%	409,015	$4,544,157	—	31 Mar 2026	13F
CITADEL ADVISORS LLC	13F	Company	0.49%	383,058	$4,255,775	—	31 Mar 2026	13F
Woodline Partners LP	13F	Company	0.47%	369,052	$4,100,168	—	31 Mar 2026	13F
UBS Group AG	13F	Company	0.46%	360,371	$4,003,721	—	31 Mar 2026	13F
VANGUARD FIDUCIARY TRUST CO	13F	Company	0.43%	338,713	$3,763,101	—	31 Mar 2026	13F
Sanjeev Narula	3/4/5	Chief Financial & Bus. Officer	— mixed-class rows	269,563 mixed-class rows	$3,439,266	—	02 Jan 2026	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.39%	305,800	$3,397,438	—	31 Mar 2026	13F
Trexquant Investment LP	13F	Company	0.37%	293,305	$3,258,619	—	31 Mar 2026	13F
Squarepoint Ops LLC	13F	Company	0.35%	275,161	$3,057,039	—	31 Mar 2026	13F
JPMORGAN CHASE & CO	13F	Company	0.36%	287,430	$3,026,637	—	31 Mar 2026	13F
Susquehanna Portfolio Strategies, LLC	13F	Company	0.34%	267,962	$2,977,058	—	31 Mar 2026	13F
Simplify Asset Management Inc.	13F	Company	0.33%	262,386	$2,915,108	—	31 Mar 2026	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.32%	254,219	$2,824,374	—	31 Mar 2026	13F
Avidity Partners Management LP	13F	Company	0.32%	249,390	$2,793,168	—	31 Mar 2026	13F
Catalio Capital Management, LP	13F	Company	0.31%	247,767	$2,752,691	—	31 Mar 2026	13F
Terrie Curran	3/4/5	President and Chief Executive, Director	— mixed-class rows	706,805 mixed-class rows	$2,399,933	—	27 Feb 2025	3/4/5
Birchview Capital, LP	13F	Company	0.25%	195,000	$2,166,450	—	31 Mar 2026	13F

Recent Insider Transactions by Companies or Individuals for Phathom Pharmaceuticals, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Asit Parikh	PHAT	Common Stock	Gift	49.7%			40,000	120,500	10 Mar 2026	by Trust
Asit Parikh	PHAT	Common Stock	Gift	-79.2%			-40,000	10,500	10 Mar 2026	Direct
Robert Charles Breedlove	PHAT	Common Stock	Tax liability	-2.19%			-1,378	61,480	27 Feb 2026	Direct
Robert Charles Breedlove	PHAT	Common Stock	Award	33.6%			15,790	62,858	27 Feb 2026	Direct
Anne Marie Cook	PHAT	Common Stock	Tax liability	-1.7%			-1,535	88,660	10 Feb 2026	Direct
Anne Marie Cook	PHAT	Common Stock	Award	3.99%			3,461	90,195	10 Feb 2026	Direct
Steven L. Basta	PHAT	Common Stock	Tax liability	-1.65%			-6,277	373,315	10 Feb 2026	Direct
Steven L. Basta	PHAT	Common Stock	Award	3.37%			12,362	379,592	10 Feb 2026	Direct
Asit Parikh	PHAT	Common Stock	Gift				80,500	80,500	23 Jan 2026	by Trust
Asit Parikh	PHAT	Common Stock	Gift	-61.4%			-80,500	50,500	23 Jan 2026	Direct
Robert Charles Breedlove	PHAT	Common Stock	Tax liability	-1.62%			-776	47,068	21 Jan 2026	Direct
Asit Parikh	PHAT	Common Stock	Options Exercise	7.16%			8,750	131,000	13 Jan 2026	Direct
Asit Parikh	PHAT	Common Stock (Right to Buy)	Options Exercise	-100%			-8,750	0	13 Jan 2026	Direct
Steven L. Basta	PHAT	Common Stock	Award	220.6%			251,034	364,820	02 Jan 2026	Direct
Steven L. Basta	PHAT	Stock Option (Right to Buy)	Award				226,156	221,156	02 Jan 2026	Direct
Anne Marie Cook	PHAT	Common Stock	Award	779.4%			75,345	85,012	02 Jan 2026	Direct
Anne Marie Cook	PHAT	Stock Option (Right to Buy)	Award				67,878	67,878	02 Jan 2026	Direct
Sanjeev Narula	PHAT	Common Stock	Award	57.4%			82,715	226,715	02 Jan 2026	Direct
Sanjeev Narula	PHAT	Stock Option (Right to Buy)	Award				42,848	42,848	02 Jan 2026	Direct
Asit Parikh	PHAT	Common Stock	Options Exercise	7.71%			8,750	122,250	19 Dec 2025	Direct
Asit Parikh	PHAT	Common Stock (Right to Buy)	Options Exercise	-50%			-8,750	8,750	19 Dec 2025	Direct
Robert Charles Breedlove	PHAT	Common Stock	Tax liability	-0.48%			-230	47,844	18 Dec 2025	Direct
Anne Marie Cook	PHAT	Common Stock	Tax liability	-44.4%			-7,703	9,667	17 Dec 2025	Direct
Anne Marie Cook	PHAT	Common Stock	Award				17,370	17,370	17 Dec 2025	Direct
Steven L. Basta	PHAT	Common Stock	Tax liability	-21.7%			-31,502	113,786	17 Dec 2025	Direct
Steven L. Basta	PHAT	Common Stock	Award	74.5%			62,038	145,288	17 Dec 2025	Direct
Steven L. Basta	PHAT	Common Stock	Tax liability	-36.8%			-48,375	83,250	28 Nov 2025	Direct
Steven L. Basta	PHAT	Common Stock	Options Exercise	216.2%			90,000	131,625	28 Nov 2025	Direct
Steven L. Basta	PHAT	Performance Shares	Options Exercise	-33.3%			-90,000	180,000	28 Nov 2025	Direct
Robert Charles Breedlove	PHAT	Common Stock	Sale	-1.09%	$7,079	$13.51	-524	47,407	03 Nov 2025	Direct
Sanjeev Narula	PHAT	Common Stock	Award				144,000	144,000	06 Oct 2025	Direct
Steven L. Basta	PHAT	Common Stock	Tax liability	-53.8%			-48,375	41,625	25 Sep 2025	Direct
Steven L. Basta	PHAT	Common Stock	Options Exercise				90,000	90,000	25 Sep 2025	Direct
Steven L. Basta	PHAT	Performance Shares	Options Exercise	-25%			-90,000	270,000	25 Sep 2025	Direct
Robert Charles Breedlove	PHAT	Common Stock	Sale	-0.95%	$5,573	$12.09	-461	47,931	05 Sep 2025	Direct
Robert Charles Breedlove	PHAT	Common Stock	Sale	-3.38%	$14,152	$8.36	-1,692	48,392	16 Jul 2025	Direct
Anne Marie Cook	PHAT	Stock Option (Right to Buy)	Award				210,000	210,000	23 Jun 2025	Direct
Frank Karbe	PHAT	Common Stock	Award	18.4%			10,500	67,500	03 Jun 2025	Direct
Frank Karbe	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
Michael F. Cola	PHAT	Common Stock	Award	35.8%			10,500	39,798	03 Jun 2025	Direct
Michael F. Cola	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
James N. Topper	PHAT	Common Stock	Award	32.7%			10,500	42,596	03 Jun 2025	Direct
James N. Topper	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
Heidi Fields	PHAT	Common Stock	Award	53.8%			10,500	30,000	03 Jun 2025	Direct
Heidi Fields	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
Mark Stenhouse	PHAT	Common Stock	Award	53.8%			10,500	30,000	03 Jun 2025	Direct
Mark Stenhouse	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
Asit Parikh	PHAT	Common Stock	Award	10.2%			10,500	113,500	03 Jun 2025	Direct
Asit Parikh	PHAT	Stock Option (Right to Buy)	Award				17,500	17,500	03 Jun 2025	Direct
James N. Topper	PHAT	Common Stock	Purchase	6.8%	$14,609	$3.86	3,780	59,403	21 May 2025	By Frazier Life Sciences X, L.P.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.